KR100852965B1 - 피페라진디온 화합물 - Google Patents

피페라진디온 화합물 Download PDF

Info

Publication number
KR100852965B1
KR100852965B1 KR1020027015025A KR20027015025A KR100852965B1 KR 100852965 B1 KR100852965 B1 KR 100852965B1 KR 1020027015025 A KR1020027015025 A KR 1020027015025A KR 20027015025 A KR20027015025 A KR 20027015025A KR 100852965 B1 KR100852965 B1 KR 100852965B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
piperazinedione
dione
methylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027015025A
Other languages
English (en)
Korean (ko)
Other versions
KR20030005336A (ko
Inventor
체-밍 텡
후이-포 왱
에릭 아이. 시. 리
온 리
지-화 구
훼이-팅 첸
얀-빙 판
야-란 첸
Original Assignee
애드파르마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애드파르마 인코포레이티드 filed Critical 애드파르마 인코포레이티드
Publication of KR20030005336A publication Critical patent/KR20030005336A/ko
Application granted granted Critical
Publication of KR100852965B1 publication Critical patent/KR100852965B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
KR1020027015025A 2000-05-09 2001-05-08 피페라진디온 화합물 Expired - Fee Related KR100852965B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30419100P 2000-05-09 2000-05-09
US60/304,191 2000-05-09
PCT/US2001/014721 WO2001095858A2 (en) 2000-05-09 2001-05-08 Piperazinedione compounds

Publications (2)

Publication Number Publication Date
KR20030005336A KR20030005336A (ko) 2003-01-17
KR100852965B1 true KR100852965B1 (ko) 2008-08-19

Family

ID=23175471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027015025A Expired - Fee Related KR100852965B1 (ko) 2000-05-09 2001-05-08 피페라진디온 화합물

Country Status (14)

Country Link
US (1) US6635649B2 (enExample)
EP (1) EP1282609B1 (enExample)
JP (1) JP5101781B2 (enExample)
KR (1) KR100852965B1 (enExample)
CN (1) CN100522949C (enExample)
AT (1) ATE417614T1 (enExample)
BR (1) BR0110745A (enExample)
CZ (1) CZ301743B6 (enExample)
DE (1) DE60137037D1 (enExample)
HU (1) HUP0302358A3 (enExample)
NO (1) NO326341B1 (enExample)
RU (1) RU2269520C2 (enExample)
WO (1) WO2001095858A2 (enExample)
ZA (1) ZA200209917B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
AU7931301A (en) 2000-08-04 2002-02-18 Dmi Biosciences Inc Method of using diketopiperazines and composition containing them
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP4674317B2 (ja) * 2002-10-02 2011-04-20 ディエムアイ アクイジション コーポレイション 疾病の判定および監視
PL2537524T3 (pl) 2003-05-15 2017-01-31 Ampio Pharmaceuticals, Inc. Leczenie chorób mediowanych przez komórki T
EP1663196A2 (en) * 2003-09-25 2006-06-07 DMI Biosciences, Inc. Methods and products which utilize n-acyl-l-aspartic acid
KR101228104B1 (ko) * 2004-02-04 2013-02-01 니리어스 파마슈티컬즈, 인코퍼레이션 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의합성방법
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2300011A4 (en) * 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
ES2593859T3 (es) * 2008-08-22 2016-12-13 British Columbia Cancer Agency Branch Moléculas pequeñas inhibidoras de la activación del extremo N del receptor de andrógenos
CA2757573A1 (en) * 2009-04-16 2010-10-21 Telik, Inc. Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
US8710062B2 (en) * 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
AU2012323320B2 (en) 2011-10-10 2017-05-11 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
AU2012328605B9 (en) 2011-10-28 2017-08-03 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
JP6723222B2 (ja) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 関節病態の治療
CN104356077B (zh) * 2014-09-11 2016-09-14 中国科学院南海海洋研究所 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
CN107530340B (zh) 2015-03-06 2021-06-08 大连万春布林医药有限公司 治疗脑肿瘤的方法
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
WO2017011399A1 (en) 2015-07-13 2017-01-19 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
MX2019009020A (es) 2017-02-01 2019-11-12 Beyondspring Pharmaceuticals Inc Metodo para reducir la neutropenia.
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
CN109580801B (zh) * 2018-06-26 2021-09-07 深圳海王医药科技研究院有限公司 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021832A1 (en) * 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
GB8609908D0 (en) * 1986-04-23 1986-05-29 Fujisawa Pharmaceutical Co Piperazine compound
US4806538A (en) * 1984-11-02 1989-02-21 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
DK181687A (da) * 1986-04-23 1987-10-24 Fujisawa Pharmaceutical Co Piperazinderivater og fremgangsmaade til fremstiling deraf
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
IL112627A0 (en) 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
US5708804A (en) * 1994-07-25 1998-01-13 International Business Machines Corp. Apparatus and method therefor of intelligently searching for information in a personal communications device
JP3795093B2 (ja) * 1994-11-25 2006-07-12 キッセイ薬品工業株式会社 １−ヒドロキシインドール誘導体
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021832A1 (en) * 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Chem. Soc. Perkin Trans. 1990, 2, 1, 127-132
Tetrahedron Letters, 1991, 32(47), pp. 6883-6884
Tetrahedron, 1999, 55(22,28), pp. 6841-6846

Also Published As

Publication number Publication date
CZ20023693A3 (cs) 2003-05-14
CZ301743B6 (cs) 2010-06-09
EP1282609B1 (en) 2008-12-17
NO20025373D0 (no) 2002-11-08
ZA200209917B (en) 2004-04-28
BR0110745A (pt) 2003-12-30
HUP0302358A2 (hu) 2003-11-28
DE60137037D1 (de) 2009-01-29
ATE417614T1 (de) 2009-01-15
JP5101781B2 (ja) 2012-12-19
WO2001095858A2 (en) 2001-12-20
CN100522949C (zh) 2009-08-05
JP2004510701A (ja) 2004-04-08
EP1282609A2 (en) 2003-02-12
KR20030005336A (ko) 2003-01-17
NO326341B1 (no) 2008-11-10
NO20025373L (no) 2002-12-13
CN1441789A (zh) 2003-09-10
EP1282609A4 (en) 2003-06-04
WO2001095858A3 (en) 2002-03-21
HUP0302358A3 (en) 2007-09-28
US20020028819A1 (en) 2002-03-07
US6635649B2 (en) 2003-10-21
RU2269520C2 (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
KR100852965B1 (ko) 피페라진디온 화합물
Chang et al. Synthesis and antiproliferative evaluations of certain 2-phenylvinylquinoline (2-styrylquinoline) and 2-furanylvinylquinoline derivatives
US7507762B2 (en) Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN105153142B (zh) 香豆素母核的呋咱衍生物及抗肿瘤活性
JP2002508007A (ja) Ｍｄｒモジュレーターとしてのイミダゾール誘導体
WO2004101570A1 (en) Sulfur-containing naphthoylimide derivatives
US7288545B2 (en) Piperazinedione compounds
BRPI0617364A2 (pt) compostos heterocÍclicos como inibidores de pstat3/il-6
US8710062B2 (en) Piperazinedione compounds
KR100819576B1 (ko) 신규 찰콘 화합물
JPS6256474A (ja) ジヒドロピリジン−２−ヒドロキシアミン類
AU2001294505B2 (en) Piperazinedione compounds
CA2408649C (en) Piperazinedione compounds
AU2001294505A1 (en) Piperazinedione compounds
EP3008073B1 (en) Thieno[2,3-b]pyridines as multidrug resistance modulators
US20060040909A1 (en) Selenophene compounds
CN112824405B (zh) 一种n-甲基依诺沙星的丙烯酮衍生物及其制备方法和应用
US20250163002A1 (en) Fused quinonoxime imidazole, onium derivatives thereof, preparation and use thereof
US20030105116A1 (en) Fused tri-heterocyclic compounds
CN111303025A (zh) 一种n-乙酰基氟罗沙星的丙烯酮衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20110819

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120821

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130813

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130813